A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease
Stopped The study has terminated due to non-safety reasons; Business Objectives have changed.
Conditions
Interventions
- DRUG: Ozanimod
- OTHER: Placebo
Sponsor
Celgene